The Open University
Epigenetic rewiring in Cerebral Cavernous Malformation disease: the role of Polycomb Repressive Complexes
Abstract
dc:description.abstractCerebral cavernous malformation (CCM) is a neuro-vascular disease characterized by capillary-venous malformations composed by enlarged and irregular vessels, almost exclusively located in the central nervous system. Cavernomas are leaky and prone to develop intracerebral hemorrhages and focal neurological deficits. CCM is caused by familial or sporadic mutations in anyone of the three CCM genes (<i>CCM1, CCM2</i> and <i>CCM3</i>). Currently, the only available treatment for CCM patients is surgical resection: an effective pharmacological therapy is missing and urgently needed.<br></br><br></br>Polycomb Repressive Complexes (PRCs) are epigenetic machineries that modulate gene repression. Functional alterations of PRCs have been associated to cancer stem cells epithelial-to-mesenchymal transition in multiple human malignancies. <br></br><br></br>Here I show that PRCs have a key role in driving “endothelial-to-mesenchymal“ transition and formation of CCM lesions, and that their pharmacological inhibition may represent a therapeutic strategy for the treatment of CCM. <br></br><br></br>I found that PRCs reshape the epigenetic landscape of <i>Ccm</i>-null endothelial cells through the repression of multiple sets of genes involved in differentiation, proliferation, inflammation and coagulation, all hallmarks of CCM disease. Then, I analyzed the role played by BMI1 and EZH2, two core subunits of PRCs. Here I report that they regulate the expression of “endothelial-to-mesenchymal” transition genes together with the aberrant proliferative and migratory features shown by <i>Ccm</i>-mutated endothelial cells. Indeed, BMI1 inhibition was effective in rescuing multiple pathological processes causative of CCM disease, both in cell lines, zebrafish and mouse CCM models, with mutations in all the three disease causative genes. <br></br><br></br>My results define a novel role played by epigenetic mechanisms and, in particular, by PRCs in regulating the maintenance of endothelial signaling and the pathological transition through a mesenchymal phenotype. Finally, I showed that the aberrant BMI1 function in CCM can be mitigated with a specific inhibitor, providing a novel therapeutic avenue for this untreatable condition.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Valentino, Mariaelena
Rights
- Language dc:language
- en